Lilly set for strong quarter after Novo profit warning

Eli Lilly is poised to report robust Q2 sales and profit next week, contrasting sharply with rival Novo Nordisk's recent profit warning that wiped $70 billion from its market value due to U.S. growth and compounding competition. Lilly's Zepbound currently dominates the U.S. obesity market with less exposure to compounding pressures, giving it a competitive advantage. Despite this, Lilly's shares still declined nearly 5% on Tuesday, reflecting investor concerns that the company could be vulnerable to aggressive pricing from Novo or a slowdown in its own obesity market growth, making its upcoming earnings and full-year outlook crucial for assessing its long-term competitive trajectory.

Analysis

Eli Lilly (LLY) is positioned for a strong second-quarter earnings report, standing in stark contrast to competitor Novo Nordisk (NVO), which recently issued a profit warning that erased $70 billion from its market value. The divergence is attributed to Lilly's superior competitive positioning in the U.S. obesity drug market. Lilly's Zepbound commands just under 60% of the market and has faced less pressure from cheaper compounded drug versions, a key factor in Novo's downgraded U.S. growth expectations. Analyst consensus forecasts Lilly to report Q2 earnings of $5.57 per share on $14.71 billion in revenue, with the company's own 2025 guidance projecting adjusted earnings between $20.78 and $22.28 per share. Despite these positive indicators, LLY shares recently fell nearly 5%, signaling investor anxiety that Lilly may not be immune to aggressive price cuts from Novo or a broader-than-expected slowdown in the obesity market. The upcoming earnings call is therefore critical, as strong results and a reaffirmation of guidance could quell these fears, while any signs of softness could validate the market's recent concerns. Furthermore, Lilly's pipeline, including the experimental oral obesity drug orforglipron slated for an approval submission by year-end, remains a key long-term differentiator.

Key Decisions for Investors

• Investors should closely scrutinize Lilly's upcoming earnings release and management commentary for any revisions to its full-year outlook, as this will be a key catalyst to either confirm its competitive edge or validate recent market fears.
• Monitor prescription data and market share trends for Zepbound versus Wegovy, paying special attention to the impact of Novo's potential price adjustments and the ongoing competition from compounded drugs.
• Given the significant performance divergence, with Lilly's stock down marginally YTD versus Novo's over 40% decline, consider the relative strength of Lilly's fundamentals as a potential basis for sector allocation, pending confirmation from its quarterly results.
• Track any updates on the development and approval timeline for the oral obesity drug orforglipron, as its successful launch represents a significant long-term growth driver and a key advantage over competitors.